Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.775
+0.055 (3.20%)
At close: Sep 17, 2026, 4:00 PM EDT
1.780
+0.005 (0.28%)
After-hours: Sep 17, 2026, 4:10 PM EDT
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
77.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| NeurAxis | 5.32M |
| Connect Biopharma Holdings | 2.95M |
| RenovoRx | 1.98M |
| iBio, Inc. | 100.00K |
GANX News
- 10 hours ago - Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference - GlobeNewsWire
- 23 days ago - Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Gain Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Gain Therapeutics reports Q2 EPS (11c), consensus (15c) - TheFly
- 6 weeks ago - Gain Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics receives FDA clearance of GT-02287 IND application - TheFly